Federal Circuit Affirms Invalidity of Ravgen Genetic Testing Patent in Streck Appeal

Introduction

In a significant ruling for the prenatal diagnostics and genetic testing industry, the U.S. Court of Appeals for the Federal Circuit affirmed the invalidity of Ravgen, Inc.’s patent covering methods for detection of genetic disorders. Case No. 23-1989, Streck, Inc. v. Ravgen, Inc., closed on January 22, 2025, after 594 days of appellate proceedings—delivering a decisive outcome that carries broad implications for patent holders asserting method claims in the molecular diagnostics space.

The Federal Circuit’s affirmance confirms that U.S. Patent No. 7,332,277 B2, directed to methods for genetic disorder detection, does not meet the threshold for patentability. For patent attorneys, IP professionals, and R&D teams operating at the intersection of genomics and clinical diagnostics, this case offers critical lessons about claim durability, appellate strategy, and the risks of asserting patents against well-resourced defendants capable of mounting robust invalidity defenses.

This ruling joins a growing body of Federal Circuit precedent scrutinizing method patents in the life sciences sector—making it essential reading for anyone managing a genetic testing IP portfolio.

Case Overview

The Parties

The Patent at Issue

The disputed patent, **U.S. Patent No. 7,332,277 B2** (Application No. US10/661,165), covers methods for detection of genetic disorders—a foundational technology area underpinning non-invasive prenatal diagnostics. The patent’s claims relate to techniques for analyzing cell-free DNA to identify chromosomal abnormalities and other genetic conditions without invasive procedures.

• • US 7,332,277 B2 — Methods for detection of genetic disorders using cell-free DNA

Legal Representation

• • Streck (Appellant): Marshall Gerstein & Borun LLP, with attorneys Isha S. Shah, Sandip Patel, Thomas Burns, and Thomas Lee Duston
• • Ravgen (Appellee): Desmarais LLP, with attorneys Brian Matty, Gabrielle E. Higgins, John M. Desmarais, and KerriAnn Limbeek

Both firms are recognized appellate IP practices, lending significant strategic weight to the arguments advanced on each side.

Litigation Timeline & Procedural History

The appeal was filed in the District of Columbia circuit region before the Court of Appeals for the Federal Circuit—the exclusive appellate forum for patent matters arising from U.S. district courts and the USPTO. The Federal Circuit’s specialized jurisdiction over patent law makes its decisions uniquely authoritative and nationally binding on patent validity questions.

The 594-day duration reflects the complexity typical of Federal Circuit appellate proceedings involving validity challenges to life sciences patents, where extensive briefing, technical expert records, and potentially oral argument contribute to extended timelines. The case originated as a patentability/invalidity action and proceeded through full appellate review before the Federal Circuit issued its affirmance.

The verdict cause is classified as an Invalidity/Cancellation Action, indicating that the core dispute centered on whether the ‘277 patent’s claims met the statutory requirements for patentability—not merely whether infringement occurred.

The Verdict & Legal Analysis

Outcome

The Federal Circuit issued a clean AFFIRMED judgment: “THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED.” The basis of termination is recorded as Unpatentable, confirming that U.S. Patent No. 7,332,277 B2 failed to survive validity scrutiny on appeal. No damages award is disclosed in the available case record, consistent with an invalidity determination that extinguishes the underlying infringement claim.

Verdict Cause Analysis

The case was litigated on grounds of patentability—specifically an invalidity/cancellation action. While the full judicial reasoning of the Federal Circuit’s opinion would be accessible via the court’s official docket and PACER, the recorded outcome establishes that the ‘277 patent’s claims were found unpatentable and that the lower-level determination was sufficiently supported to warrant affirmance on appeal.

In the context of genetic method patents, invalidity challenges commonly proceed on multiple grounds including:

• Obviousness (35 U.S.C. § 103): Prior art combinations that render the claimed method obvious to a person of ordinary skill in molecular biology or prenatal diagnostics
• Anticipation (35 U.S.C. § 102): Single prior art references disclosing the claimed method steps
• Subject matter eligibility (35 U.S.C. § 101): Post-Alice/Mayo challenges to method claims directed to natural phenomena or abstract diagnostic correlations

The Federal Circuit’s willingness to affirm the unpatentability finding signals that the invalidity arguments presented—whether based on prior art, claim construction, or statutory grounds—were well-supported by the record developed at the trial or inter partes review level.

Legal Significance

This ruling carries meaningful precedential weight in the genetic diagnostics patent space for several reasons:

• Ravgen’s portfolio strategy scrutinized: Ravgen had pursued infringement claims against multiple diagnostic companies. An affirmance of invalidity at the Federal Circuit level materially undermines the enforceability of related patent family members and weakens Ravgen’s broader licensing leverage.
• Method claim vulnerability: The case reinforces that method patents in the genetic testing field—particularly those covering diagnostic detection methods—face elevated invalidity risk, especially when asserted against defendants with resources to mount comprehensive prior art challenges.
• Appellate deference standards: The Federal Circuit’s affirmance reflects that the factual and legal foundations supporting the invalidity finding were robust enough to survive de novo claim construction review and clear-error scrutiny on fact questions.

Strategic Takeaways

For Patent Holders: Ravgen’s experience underscores the importance of stress-testing patent claims against the prior art landscape before initiating litigation. Claims that appear commercially valuable but rest on a crowded prior art field are vulnerable to invalidity challenges that can nullify assertion strategies entirely.

For Accused Infringers: Streck’s successful defense demonstrates the value of investing in thorough prior art searches and validity analysis as the first line of defense against patent assertions. Engaging experienced appellate IP counsel—here, Desmarais LLP—to preserve and develop the invalidity record is equally critical.

For R&D Teams: Freedom-to-operate (FTO) analyses in the genetic diagnostics field should now account for the weakened enforceability of Ravgen’s ‘277 patent family. R&D leaders should revisit prior FTO clearance opinions that treated this patent as a potential blocking risk.

Industry & Competitive Implications

The Federal Circuit’s ruling in Streck v. Ravgen arrives against a backdrop of sustained legal pressure on non-invasive prenatal testing patents. Ravgen had been one of the more aggressive patent asserters in the NIPT space, filing suits against major diagnostics players. An invalidity affirmance at the Federal Circuit level is a significant commercial setback that limits Ravgen’s ability to extract licensing revenue from the ‘277 patent going forward.

For the broader **molecular diagnostics and genomics industry**, the decision contributes to a gradually clearing IP landscape in prenatal genetic testing—potentially lowering barriers for companies developing next-generation NIPT products. Companies that previously entered licensing agreements or design-around programs based on the ‘277 patent should evaluate whether those arrangements require revisiting in light of the patent’s invalidation.

The case also reflects a broader industry trend: diagnostics companies facing patent assertions are increasingly willing to litigate through to final Federal Circuit resolution rather than settle, particularly when the asserted patent presents strong invalidity arguments. This trend has practical implications for patent monetization strategies in the life sciences sector.

Licensing professionals and IP managers should monitor whether Ravgen pursues continuation claims or related family members in response to the ‘277 patent’s invalidity, a common portfolio management response to adverse validity rulings.

Frequently Asked Questions

• What patent was at issue in Streck v. Ravgen?
  U.S. Patent No. 7,332,277 B2 (Application No. US10/661,165), covering methods for detection of genetic disorders.
• What was the Federal Circuit’s ruling in Case No. 23-1989?
  The court affirmed the lower-level finding, declaring the patent unpatentable and closing the case on January 22, 2025.
• How does this ruling affect genetic testing patent litigation?
  It weakens Ravgen’s assertion position and signals continued Federal Circuit scrutiny of method patents in the molecular diagnostics field, particularly invalidity challenges grounded in prior art.

For case documents, consult the Federal Circuit’s official docket or search Case No. 23-1989 on PACER. Patent details are available via the USPTO Patent Center.